M. Mackenzie

发表

Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies

J. Schuurs-Hoeijmakers, A. Hoischen, J. Hehir-Kwa, 2019, Genome Medicine.

A dominant-negative GFI1B mutation in the gray platelet syndrome.

M. Kempers, J. Jansen, E. Fransen, 2013, New England Journal of Medicine.

Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome

D. Swinkels, R. Raymakers, T. D. de Witte, 2010, British journal of haematology.

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

D. Swinkels, A. Stamatoullas, C. Craddock, 2020, Leukemia.

High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients

A. Hagenbeek, D. de Jong, H. Kluin-Nelemans, 2009, British journal of haematology.

Can multiple myeloma become a curable disease

J. Raemaekers, E. Jaffe, S. Swerdlow, 2011 .

Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

D. de Jong, P. Sonneveld, G. Ossenkoppele, 2006, Blood.

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

P. Sonneveld, B. van der Holt, H. Kluin-Nelemans, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An X;9 translocation, primary amenorrhea, and hypothalamic dysfunction.

H. A. Gardner, M. Mackenzie, J. Mcconnon, 1983, American journal of medical genetics.

X-linked sideroblastic anaemia due to ALAS₂ mutations in the Netherlands: a disease in disguise.

D. Swinkels, M. Coenen, R. Raymakers, 2014, The Netherlands journal of medicine.

Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

M. Kersten, D. de Jong, H. Kluin-Nelemans, 2020, British journal of haematology.

Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high‐dose methotrexate, and R‐DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study

M. Kersten, J. Baars, P. Lugtenburg, 2017, Hematological oncology.

7 Management of 1000 patients with low- and intermediate-1 risk myelodysplastic syndromes in the European LeukemiaNet MDS Registry

Alexandra G. Smith, P. Fenaux, E. Hellström-Lindberg, 2011 .

Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2013 .

Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2010 .

Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2011 .

Prognostic Relevance of the Kinetics of Worsening of Cytopenias in Lower-Risk MDS: A Substudy From the European Leukemianet Low Risk MDS (EUMDS) Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2012 .

A case of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting with spontaneous splenic rupture: an extremely unusual presentation

K. Hebeda, J. V. van Krieken, M. Mackenzie, 2000, Virchows Archiv.

Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin’s Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

P. Sonneveld, G. Ossenkoppele, G. Verhoef, 2006 .

Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo.

I. Jackson, S. Jordan, P. Budd, 1997, Developmental biology.

The CAG repeat within the androgen receptor gene in male breast cancer patients

K. Kurian, A. Wyllie, I. Kunkler, 2000, Journal of medical genetics.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders

D. Swinkels, G. Brittenham, J. Hendriks, 2016, Haematologica.

Increased vascularization predicts favorable outcome in follicular lymphoma.

J. Raemaekers, J. A. van der Laak, G. Borm, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma in the frail elderly: A phase II EORTC trial with a progressive and cautious treatment emphasizing geriatric assessment

D. de Jong, D. Jong, M. Debois, 2011 .

Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma

P. Sonneveld, H. Kluin-Nelemans, P. Kluin, 2005, Leukemia.

Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas

C. Meijer, G. Ossenkoppele, C. Meijer, 2004, Leukemia.

The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma.

J. Raemaekers, G. Borm, A. Koster, 2007, Haematologica.

Validation of the revised international prognostic scoring system (IPSS‐R) in patients with lower‐risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2015, British journal of haematology.

Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug-induced amenorrhoea, age and the progesterone receptor status of the tumour.

J. Raemaekers, L. Beex, T. Benraad, 1988, European journal of cancer & clinical oncology.

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance

L. Saft, P. Fenaux, D. Mikulenková, 2017, Annals of Hematology.

A polymorphic tetranucleotide repeat in the CYP19 gene and male breast cancer

K. Kurian, A. Wyllie, I. Kunkler, 2000, British Journal of Cancer.

Castleman disease and paraneoplastic pemphigus

M. Mackenzie, E. N. Kop, 2010, Canadian Medical Association Journal.

Early Mortality in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European Leukemianet MDS (EUMDS) Registry

P. Fenaux, E. Hellström-Lindberg, U. Germing, 2012 .

A dominant-negative GFI1B mutation in the gray platelet syndrome.

M. Kempers, J. Jansen, E. Fransen, 2014, The New England journal of medicine.